Loading…
Loading…
HSKA (Heska Corporation) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
ATHENS, Ga.--(BUSINESS WIRE)--Dalan Animal Health, Inc. (“Dalan”), the biotech company pioneering insect health with the world’s first honey bee vaccine, is proud to announce its first product shipment to a commercial beekeeper. The shipment is for Trevor Tauzer of Tauzer Apiaries in California and contains 500 doses, potentially protecting 25 million bees at an average of 50,000 bees per hive. This milestone follows the U.S. Department of Agriculture (USDA) granting a conditional license to Dalan's first-in-class honeybee vaccine earlier this year. The vaccine is indicated to protect honeybees against the devastating American Foulbrood disease caused by the bacteria Paenibacillus larvae. Honeybees are a critical component of agriculture. One-third of the global food supply relies on pollination, and healthy commercial hives are essential to secure high crop yields. However, honeybee colonies are plagued by American Foulbrood, with previously no safe and sustainable solution for disease prevention. Overt clinical cases of American Foulbrood are notifiable in the USA and Canada, and the only treatment method to limit the further spread of disease to other colonies relies on the incineration of bees and infected hives and equipment. Tauzer, also a board member of the California State Beekeepers Association, said, “We are excited about the arrival of Dalan's honey bee vaccine. This innovative solution will help honeybees prevent infection, avoid treatments, and focus on other crucial aspects of maintaining our bee's health”. Tauzer plans to sell vaccinated queen bees through his queen-producing operation, Honey Bee Genetics, beginning this year. Queens can be purchased at honeybeegenetics.com Dr. Annette Kleiser, CEO of Dalan Animal Health, emphasized the importance of the vaccine, stating, “Our mission is to protect our pollinators and promote sustainable agriculture. As global population growth and climate change continue, honeybee pollination will be increasingly vital to secure our food supply. This vaccine is a game-changer in safeguarding honeybees, and we're excited to be at the forefront of revolutionizing insect care, which will ultimately impact global food production.” Beekeepers interested in safeguarding their colonies with Dalan's vaccine can visit the website at https://www.dalan.com/contact or call 844-483-2526. The honey bee vaccine, manufactured by Diamond Animal Health (Des Moines, IA), a wholly-owned subsidiary of Heska (NASDAQ: HSKA), will initially be distributed on a limited basis to commercial beekeepers and queen producers. About the vaccine Dalan's vaccine uses killed whole-cell Paenibacillus larvae bacteria and is administered by mixing it into queen feed consumed by worker bees. The vaccine is incorporated into the royal jelly by the worker bees, who then feed it to the queen. The queen ingests the vaccine, and fragments are deposited in her ovaries, providing immunity to the developing larvae. The non-GMO vaccine can be used in organic agriculture, and pivotal efficacy studies have shown its potential to reduce larval death associated with American Foulbrood infections caused by P. larvae. About Dalan Animal Health, Inc Dalan Animal Health (www.dalan.com) is dedicated to preventing diseases that affect invertebrates, increasing profitability and yield for producers worldwide. This platform technology uses transgenerational immune priming, allowing the maternal animal to pass immune modulators (e.g., antigens, anti-microbial molecules) to the next generation larvae before they hatch. Dalan plans to develop vaccines for other honeybee diseases and underserved industries, such as shrimp, mealworms, and insects used in agriculture. The company is headquartered in Athens, Georgia, at the University of Georgia’s Innovation Hub.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Heska Corporation (NasdaqCM: HSKA) to Mars, Incorporated. Under the terms of the proposed transaction, shareholders of Heska will receive $120.00 in cash for each share of Heska that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-hska/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Heska (HSKA) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.27 per share a year ago.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Heska Corporation (NasdaqCM: HSKA) to Mars, Incorporated. Under the terms of the proposed transaction, shareholders of Heska will receive $120.00 in cash for each share of Heska that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-hska/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit ksfcounsel.com.
NEW YORK , April 3, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Heska Corporation (NASDAQ: HSKA)'s sale to Mars, Incorporated for $120.00 per share. If you are a Heska shareholder, click here to learn more about your rights and options.
Heska and privately-held Mars have agreed to a buyout offer of $120 per share. This deal underscores the high-growth potential of pet products companies.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Heska Corporation (NASDAQ: HSKA) to Mars, Incorporated for $120.00 per share is fair to Heska shareholders. Halper Sadeh encourages Heska shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Heska and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Heska shareholders; (2) determine whether Mars is underpaying for Heska; and (3) disclose all material information necessary for Heska shareholders to adequately assess and value the merger consideration. On behalf of Heska shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. Halper Sadeh encourages Heska shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Heska Corporation (NASDAQ:HSKA ) Q4 2022 Earnings Conference Call February 28, 2023 11:00 AM ET Company Participants Jon Aagaard - Investor Relations Kevin Wilson - Chief Executive Officer and President Catherine Grassman - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler Erin Wright - Morgan Stanley Ben Haynor - Alliance Global Partners Jim Sidoti - Sidoti & Company Operator Greetings. Welcome to the Heska Corporation Fourth Quarter and Full-Year 2022 Earnings Conference Call.
No recent filings indexed.